Status:
COMPLETED
Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
Lead Sponsor:
Gilles Boire
Collaborating Sponsors:
Procter and Gamble
Conditions:
Osteoporosis
Muscular Dystrophy
Eligibility:
All Genders
5-18 years
Phase:
PHASE4
Brief Summary
By supplying an adequate amount of calcium and vitamin D with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractu...
Detailed Description
Children with muscular dystrophy, as well as children with other chronic diseases (e.g. cystic fibrosis, chronic inflammatory arthritis) are at risk to develop fragility fractures both due to the dise...
Eligibility Criteria
Inclusion
- Osteoporosis or osteopenia
- Severe muscular dystrophy or cystic fibrosis
- May use corticosteroids
Exclusion
- Inability to consent or to take drugs by mouth
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01882400
Start Date
May 1 2001
End Date
September 1 2007
Last Update
January 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4